Catalytically Hyperactive Variant of Human APOBEC3G Protein

Researchers at the National Cancer Institute (NCI) have developed a highly active variant of the catalytic domain APOBEC3G with higher ssDNA affinity. This variant may be used to develop therapeutics for AIDS, and may also be used as a tool of gene editing techniques. This hyperactive variant of the human APOBEC3G protein (hereby called CTD2) can be used as a tool to edit human genes in combination with the CRISPR/Cas9 system. CTD2 is selective to a specific target DNA sequence, soluble, and catalytically hyperactive, which makes CTD2 the ideal molecule to use in the aforementioned gene editing, using the CRISPR/Cas9 system.  IC: NCINIH Ref. No.: E-150-2018Advantages: The variant of the catalytic domain of APOBEC3G has high affinity to ssDNA substrates as apparent dissociation constant, Kd, is 55 µMThe variant of the catalytic domain of APOBEC3G can catalyze deamination of cytosines in single stranded DNA 20 times faster than the wild type catalytic domain of APOBEC3GThe variant of the catalytic domain of APOBEC3G is 4 times more soluble than the wild type catalytic domain of APOBEC3GApplications: Therapeutic for HIVGene EditingUpdated On: Oct 15, 2018Date Published: Monday, October 15, 2018Provider Classifications: Publications: Patent Application: 62/673,591Licensing Contacts: Lead Inventor: Inventor IC: NCIInventor Lab URL: https://ccr.cancer.gov/Basic-Research-Laboratory/hiroshi-matsuoLPM FIrst Name: ...

Source: NIH OTT Licensing Opportunities - October 15, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research